TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05842681

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: A single daily oral dose of Azithromycin tablet 500 mg for five days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: methylprednisolone 500 mg single intra-venous daily dose for three days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: methylprednisolone 500 mg single intra-venous daily dose for three days
Study: NCT05509699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib
Description: The recommended dosage is 250 mg orally once daily (QD) within 1 hour after breakfast for continuous administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1/L1
Description: Anti-PD-1/L1 therapy, Q3W or Q4W, the same immune checkpoint inhibitor from patients' first-line therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1/L1
Description: Anti-PD-1/L1 therapy, Q3W or Q4W, the same immune checkpoint inhibitor from patients' first-line therapy.
Study: NCT06353880

Intervention type: OTHER
Intervention: Participants will be categorized into three groups based on BMI and the presence of pudendal fat deposition.
Description: Participants will be categorized into three groups based on BMI and the presence of pudendal fat deposition. Sperm quality parameters, including count, motility, and morphology, will be assessed through semen analysis. Additionally, hormonal profiles related to reproductive health will be evaluated.

Intervention type: OTHER
Intervention: Participants will be categorized into three groups based on BMI and the presence of pudendal fat deposition.
Description: Participants will be categorized into three groups based on BMI and the presence of pudendal fat deposition. Sperm quality parameters, including count, motility, and morphology, will be assessed through semen analysis. Additionally, hormonal profiles related to reproductive health will be evaluated.

Intervention type: OTHER
Intervention: Participants will be categorized into three groups based on BMI and the presence of pudendal fat deposition.
Description: Participants will be categorized into three groups based on BMI and the presence of pudendal fat deposition. Sperm quality parameters, including count, motility, and morphology, will be assessed through semen analysis. Additionally, hormonal profiles related to reproductive health will be evaluated.
Study: NCT05095987

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Appendectomy
Description: Laparoscopic Appendectomy for acute uncomplicated appendicitis in children
Study: NCT04698733

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BEST™ HVPC microcurrent electrical stimulation Pro-Sport Ultra® device
Description: Participants will receive two (2) 20-minute treatments a week on nonconsecutive days for 6 weeks in the clinic. At the end of 6 weeks, participants will have a 6-week pause in treatment.~Active Avazzia PRO-Sport Ultra® medical device, BEST™ HVPC microcurrent electrical stimulation, FDA cleared for pain relief
Study: NCT05505032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: Determination of FiO2 threshold value as an indicator of hyperoxemia in anesthesia stages.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: Determination of FiO2 threshold value as an indicator of hyperoxemia in anesthesia stages.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: Determination of FiO2 threshold value as an indicator of hyperoxemia in anesthesia stages.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Masimo Root Radical 7
Description: We use it to measure the oxygen reserve index (ORi).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Masimo Root Radical 7
Description: We use it to measure the oxygen reserve index (ORi).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Masimo Root Radical 7
Description: We use it to measure the oxygen reserve index (ORi).
Study: NCT04886986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 225Ac-J591
Description: 30 - 40 KBq/kg (dose-escalation) every 8 weeks, for up to 2 cycles. Administered together with 177Lu-PSMA-I\&T. Intravenous administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-I&T
Description: 6.8 GBq (fixed dose) every 8 weeks, for up to 2 cycles. Administered together with 225Ac-J591. Intravenous administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-11
Description: \[185 ±74 MBq or 5 ±2 mCi\] intravenous during screening, 12 weeks, 24 weeks. Imaging agent for PSMA PET/CT.
Study: NCT05993611

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Chimeric Antigen Receptor T-Cell Therapy
Description: Given CD6-CAR Tregs IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study: NCT06471374

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Circadian rhythm assessment
Description: Participants will arrive approximately 8 hours before participant's scheduled bedtime to practice ability to think testing and a 9-hour sleep study. Participants will live in the laboratory for approximately 66 hours (2.75 days). Upon awakening in the morning, participants will start a routine of up to 39 hours of wakefulness, under bedrest conditions. Saliva will be sampled frequently and blood will be drawn 3 times. Reaction time, ability to think, and subjective rating tests will be performed frequently. Participants will be provided scheduled bathroom breaks when participants will use a commode next to the bed. Outside these scheduled bathroom breaks, participants will be provided a bedpan to use to go to the bathroom. At the end of the research procedures for Visit 4 participants will be given a recovery sleep opportunity and be discharged from the lab in the morning near participant's typical waketime.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Light sensitivity assessment
Description: Participants will arrive in the afternoon to practice ability to think testing and a 9-hour sleep study. Participants will live in the laboratory for approximately 48 hours (2 days). Upon awakening in the morning, participants will be exposed to dim candlelight and then later in the day alternating intensities of dim and room light when we keep participants awake for up to 23 hours (We will ask participants to remain in bed seated for \~12.5 hours). Saliva will be sampled frequently. Reaction time, ability to think, and subjective rating tests will be performed frequently. Participants will then have a second 9-hour sleep opportunity.
Study: NCT05880511

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation
Description: Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive, non-painful procedure used to relieve chronic pain and promote short-term changes. The abductor pollicis brevis (APB) muscle of the left motor cortex will be targeted using neuronavigation software. 2000 pulses will be delivered at 10 Hz stimulation. Stimulation will be delivered at 80% of the resting motor threshold obtained from the right APB muscle. The delivery of rTMS requires \~ 11.5 minutes in total.
Study: NCT06157099

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies
Study: NCT05880511

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Augmented Reality Sensorimotor Training
Description: Sensorimotor training is a non-invasive, non-painful procedure using augmented reality to present virtual objects which cue motor action. Augmented reality allows us to project virtual objects overlaid on the user's actual environment. The sensorimotor training task involves making movements with the head and neck such that a target crosshair presented in the centre of the glasses is moved to a virtual target that is presented in the user's environment. Participants will perform 20 minutes of sensorimotor training. The goal of augmented reality sensorimotor training is to promote goal directed actions using the head and neck.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Augmented Reality Sensorimotor Training
Description: Sensorimotor training is a non-invasive, non-painful procedure using augmented reality to present virtual objects which cue motor action. Augmented reality allows us to project virtual objects overlaid on the user's actual environment. The sensorimotor training task involves making movements with the head and neck such that a target crosshair presented in the centre of the glasses is moved to a virtual target that is presented in the user's environment. Participants will perform 20 minutes of sensorimotor training. The goal of augmented reality sensorimotor training is to promote goal directed actions using the head and neck.
Study: NCT05993611

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Undergo leukapheresis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Undergo lumbar puncture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI/CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT05880511

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Repetitive transcranial magnetic stimulation
Description: Sham repetitive transcranial magnetic stimulation (rTMS) is a non-invasive, non-painful procedure. The abductor pollicis brevis (APB) muscle of the left motor cortex will be targeted using neuronavigation software. During the sham, participants will hear and experience the clicking from the device but will not be provided with any stimulation. The delivery of sham rTMS requires \~ 11.5 minutes in total.
Study: NCT06582030

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment
Description: Ancillary studies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment
Description: Ancillary studies
Study: NCT06492226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKF-INS(A)
Description: Single subcutaneous dose of 0.3 U/kg administration over three treatment periods

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EU-NovoRapid®
Description: Single subcutaneous dose of 0.3 U/kg administration over three treatment periods
Study: NCT05993611

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo x-ray imaging
Study: NCT06582030

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment
Description: Ancillary studies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment
Description: Ancillary studies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment
Description: Ancillary studies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Activity
Description: View the chronically relapsing brain disease vignette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Activity
Description: View the brain disease vignette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Activity
Description: View the disease vignette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Activity
Description: View the illness vignette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Activity
Description: View the disorder vignette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Activity
Description: View the problem vignette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: Attend a SAS workshop

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: Attend a SAS workshop

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: Attend a SAS workshop

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: Attend a SAS workshop

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: Attend a SAS workshop
Study: NCT06581913

Intervention type: OTHER
Intervention: Behavioral assessment
Description: Eating Awareness, Acceptance of Food Cravings, Healthy Life Awareness Health Perception
Study: NCT06582485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iCM012 solution 2 mg/mL
Description: 200 mL IMP solution is administered ex vivo by gravity as single infusion through the renal artery/-ies over a period of 5-10 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 200 mL IMP solution is administered ex vivo by gravity as single infusion through the renal artery/-ies over a period of 5-10 minutes.
Study: NCT05081986

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Single-pulse transcranial magnetic stimulation and theta-burst stimulation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: Single-pulse transcranial magnetic stimulation and theta-burst stimulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cycloserine
Description: Cycloserine 100mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo capsule matched to cycloserine capsule
Study: NCT05096650

Intervention type: PROCEDURE
Group type: OTHER
Intervention: mesotherapy of platelet rich plasma and platelet poor plasma
Description: Each case will receive 3 sessions of injection therapies with one month interval. Each case will receive platelet rich plasma therapy on one side of the face. The other side of the face was treated with platelet poor plasma.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mesotherapy of platelet rich plasma and platelet poor plasma
Description: Each case will receive 3 sessions of injection therapies with one month interval. Each case will receive platelet rich plasma therapy on one side of the face. The other side of the face was treated with platelet poor plasma.
Study: NCT05976165

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breath Testing
Description: Subjects drink a small carbohydrate solution, and then provide a breath sample every 15 minutes for one hour, and then every 30 minutes for the next two hours
Study: NCT06492226

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: US-NovoLog®
Description: Single subcutaneous dose of 0.3 U/kg administration over three treatment periods
Study: NCT05867992

Intervention type: OTHER
Intervention: Type of trauma
Description: Patients in case group have the severe traumatic brain injury, while patients in control group have the traumatic bone fracture without brain injury.

Intervention type: OTHER
Intervention: Type of trauma
Description: Patients in case group have the severe traumatic brain injury, while patients in control group have the traumatic bone fracture without brain injury.
Study: NCT06288685

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous A1 pulley release
Description: Treatment trigger finger by release A1 pulley by percutaneous procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: percutaneous A1 pulley release
Description: Treatment trigger finger by release A1 pulley by percutaneous procedure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone
Description: Triamcinolone 40mg/ml 1 ml injection concomitant percutaneous A1 pulley release
Study: NCT05986630

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEOSYAL® TPVM
Description: Injection of TEOSYAL® TPVM at Baseline~Optional Touch-up treatment at 4 weeks if needed to achieve optimal correction as judged by the PI.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: COMPARATOR
Description: Injection of a COMPARATOR at Baseline~Optional Touch-up treatment at 4 weeks if needed to achieve optimal correction as judged by the PI.
Study: NCT05258201

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strain-counterstrain
Description: Strain-counterstrain is also used for manual Trigger Point processing. This involves identifying active TRP and then applying pressure until a ridiculous reaction occurs. The area is then positioned to reduce tension in the injured muscle and later reduce tripod pain. When the pain subsides, the tissues that are most stressed feel relaxed and there is a local decrease in the ground

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle Energy Technique
Description: Muscle Energy Technique is a common way to achieve muscle tension release (stop) before stretching other's adductor muscles
Study: NCT05758857

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Guidelines-based physical activity
Description: Through a combination of exercise trainer-led in-person and virtual sessions, as well as counselling for independent aerobic exercise, participants will be guided to achieve 150 weekly minutes of moderate-intensity aerobic activity and twice weekly whole-body muscle strengthening.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Guidelines-based physical activity
Description: Through a combination of exercise trainer-led in-person and virtual sessions, as well as counselling for independent aerobic exercise, participants will be guided to achieve 150 weekly minutes of moderate-intensity aerobic activity and twice weekly whole-body muscle strengthening.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Guidelines-based healthy eating
Description: One-on-one phone/virtual counselling from a registered dietitian to change dietary habits to be in line with Canada's Food Guide.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Stretching exercise
Description: Twice weekly virtual instructor-led whole-body stretching class.
Study: NCT06223802

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: biodex training
Description: women group with a number of 29 women receiving 3-time biodex training per week, every time will be 10 minutes for 12 weeks
Study: NCT04736745

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPN59011
Description: Powder and solvent for solution for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPN59011
Description: Powder and solvent for solution for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPN59011
Description: Powder and solvent for solution for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPN59011
Description: Powder and solvent for solution for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Azzalure
Description: Powder for solution for injection
Study: NCT05442827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR7280 tablets
Description: SHR7280 tablets 300mg for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR7280 tablets
Description: SHR7280 tablets 400mg for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PlaceboSHR7280 tablets blank preparation
Description: Placebo group: SHR7280 tablets blank preparation for 12 weeks
Study: NCT05572489

Intervention type: DIAGNOSTIC_TEST
Intervention: visual pain scale Beck depression scale Pain catastrophizing scale Short Form-36 Standard Mini mental test Montreal cognitive assessment scale
Description: evaluation of pain, fatigue, mood, quality of life, cognitive status
Study: NCT05289323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neostigmine Methylsulfate
Description: 0.5 mg ampule (1 ml) will be diluted in 4 ml dextrose 5% to make a solution of 100 μg/ml, 0.2 ml of this solution will be added to 2.5 ml of hyperbaric bupivacaine 0.5 % used for intrathecal injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dextrose 5%/Nacl 0.9% Inj
Description: one ml of normal saline 0.9 % will be mixed with 4 ml dextrose 5 % in the five-milliliter syringe. 0.2 ml of this mixture will be prepared at a one-milliliter identical syringe.
Study: NCT05571605

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants randomized to this arm will exercise on a stationary bicycle.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Stretching
Description: Participants randomized to this arm will perform stretching and balance exercise.
Study: NCT04673539

Intervention type: DIAGNOSTIC_TEST
Intervention: Spanish version of the Brief-BESTest in stroke patients
Description: Adaptation and validation of the Spanish version of the Brief-BESTest in stroke Patients
Study: NCT05877092

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: implants with overdentures
Description: two implants with bar attachment placed in interforaminal of the mandible mandible of the participants, the patients were delivered conventional upper complete denture constructed from heat cured acrylic rein, but in implanted mandibular arch they were received complete overdenture constructed from heat cured acrylic resin for Group I, and complete thermoplastic denture was constructed for Group II.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: implants with overdentures
Description: two implants with bar attachment placed in interforaminal of the mandible mandible of the participants, the patients were delivered conventional upper complete denture constructed from heat cured acrylic rein, but in implanted mandibular arch they were received complete overdenture constructed from heat cured acrylic resin for Group I, and complete thermoplastic denture was constructed for Group II.
Study: NCT06167109

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CTV optimized IMRT
Description: The contralateral CTV1 was defined as a subclinical disease consisting of 5mm margin surrounding GTVnx.The CTV2 was defined as a potentially involved regions consisting of 5mm margin surrounding CTV1, and contralateral CTV2 only included the pharyngeal recess.
Study: NCT06519188

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nebulization application with 5 ml isotonic sodium chloride
Description: Nebulization application with 5 ml isotonic sodium chloride in the morning and evening for two months.